Dizal (Jiangsu) Pharmaceutical Co., Ltd. in 1 story
The narratives 688192.SS currently appears in, with its side and exposure in each.
Bull side
1 story- China Becomes Pharma's Global R&D Engine
688192.SS in “China Becomes Pharma's Global R&D Engine”
FadingExposure: not rated yetWestern drugmakers are licensing clinically validated Chinese molecules rather than relying solely on expensive in-house discovery.
Dizal has produced clinically validated precision-oncology drugs such as sunvozertinib and represents China's growing ability to originate globally relevant targeted therapies.
Bear side
0 storiesNo bear-side stories for 688192.SS yet.